Edition:
United States

Oramed Pharmaceuticals Inc (ORMP.OQ)

ORMP.OQ on NASDAQ Stock Exchange Capital Market

8.92USD
3:59pm EST
Change (% chg)

$0.38 (+4.45%)
Prev Close
$8.54
Open
$8.32
Day's High
$8.98
Day's Low
$8.32
Volume
21,413
Avg. Vol
14,071
52-wk High
$11.34
52-wk Low
$5.82

Chart for

About

Oramed Pharmaceuticals Inc. (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible... (more)

Overall

Beta: 1.14
Market Cap(Mil.): $122.17
Shares Outstanding(Mil.): 14.31
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 186.11 15.67
EPS (TTM): -- -- --
ROI: -- -11.32 34.62
ROE: -- -35.69 16.00

BRIEF-Oramed receives approval for clinical study to treat NASH

* Oramed receives regulatory approval to conduct clinical study for treatment of NASH with its oral insulin capsule

Nov 14 2017

BRIEF-Oramed pharmaceuticals ‍concludes its meeting with U.S. FDA regarding its oral insulin formulation​

* ‍Concluded its meeting with U.S. FDA regarding ORMD-0801, company's novel oral insulin formulation​

Sep 05 2017

BRIEF-Oramed Pharmaceuticals Inc's CFO Yifat Zommer resigned from her positions with co per personal reasons

* Oramed Pharmaceuticals Inc - on July 18, yifat zommer, cfo of co resigned from her positions with co per personal reasons, effective August 1, 2017

Jul 21 2017

BRIEF-Oramed announces dual-listing on Tel Aviv stock exchange

* Oramed Pharmaceuticals Inc - ‍Based on current market capitalization of company, it is expected that Oramed will be included in TA SME-60 index​

Jul 05 2017

BRIEF-Oramed granted Japanese patent for combination insulin and glp-1 analog capsule

* Oramed granted Japanese patent for combination insulin and glp-1 analog capsule

Jun 27 2017

Earnings vs. Estimates